Abbott Laboratories Dividends and Buybacks
Dividend criteria checks 5/6
Abbott Laboratories is a dividend paying company with a current yield of 1.75% that is well covered by earnings.
Key information
1.7%
Dividend yield
0.4%
Buyback Yield
| Total Shareholder Yield | 2.2% |
| Future Dividend Yield | 2.1% |
| Dividend Growth | 9.9% |
| Next dividend pay date | n/a |
| Ex dividend date | n/a |
| Dividend per share | US$2.360 |
| Payout ratio | 29% |
Recent dividend and buyback updates
Recent updates
Abbott Laboratories' (NYSE:ABT) Business Is Yet to Catch Up With Its Share Price
Feb 17
Does Abbott Laboratories (NYSE:ABT) Deserve A Spot On Your Watchlist?
Feb 05Abbott Laboratories: Now Back In The Buy Zone (Rating Upgrade)
Jan 23Does Abbott Laboratories (NYSE:ABT) Have A Healthy Balance Sheet?
Jan 13Abbott Laboratories Q4 2024 Earnings Preview
Jan 08Abbott Laboratories: A Future-Driven Pharma Brand With A Robust Pipeline
Dec 21Calculating The Fair Value Of Abbott Laboratories (NYSE:ABT)
Dec 01Abbott Laboratories: Investors Should Wait For A Pullback
Nov 25Investors Will Want Abbott Laboratories' (NYSE:ABT) Growth In ROCE To Persist
Oct 31Abbott Laboratories: Long-Term Optimism, Short-Term Overvaluation
Oct 21Abbott: Challenging Comparables, Unappealing Value Limit The Incentive To Go Long Ahead Of Q3 Event
Oct 14Does Abbott Laboratories (NYSE:ABT) Have A Healthy Balance Sheet?
Oct 11Why We're Not Concerned About Abbott Laboratories' (NYSE:ABT) Share Price
Sep 27Abbott Laboratories: Cardiovascular Disease Has Been A Tailwind, But Things Could Change
Sep 11A Look At The Intrinsic Value Of Abbott Laboratories (NYSE:ABT)
Aug 16Abbott Laboratories: Driving Value By Scaling Innovations
Aug 13Abbott Laboratories: A Strong Healthcare Stock For Long-Term Dividend Growth Investors
Aug 05Abbott Laboratories: When Double-Digit Device Growth Apparently Isn't Enough
Jul 13These 4 Measures Indicate That Abbott Laboratories (NYSE:ABT) Is Using Debt Reasonably Well
Jul 01Abbott Laboratories (NYSE:ABT) Is Doing The Right Things To Multiply Its Share Price
Jun 18Investors Still Waiting For A Pull Back In Abbott Laboratories (NYSE:ABT)
Jun 04Abbott Laboratories: Why I Agree With Wall Street On This One
Jun 04Abbott Laboratories: Buying More Of This Top-Notch Dividend Growth Stock
May 18Abbott Laboratories: Organic Growth Will Be Key To Q1 Earnings
Apr 17Estimating The Intrinsic Value Of Abbott Laboratories (NYSE:ABT)
Apr 15Stability and Growth of Payments
Fetching dividends data
Stable Dividend: ABT's dividends per share have been stable in the past 10 years.
Growing Dividend: ABT's dividend payments have increased over the past 10 years.
Dividend Yield vs Market
| Abbott Laboratories Dividend Yield vs Market |
|---|
| Segment | Dividend Yield |
|---|---|
| Company (ABT) | 1.7% |
| Market Bottom 25% (US) | 1.5% |
| Market Top 25% (US) | 4.5% |
| Industry Average (Medical Equipment) | 1.6% |
| Analyst forecast (ABT) (up to 3 years) | 2.1% |
Notable Dividend: ABT's dividend (1.75%) is higher than the bottom 25% of dividend payers in the US market (1.48%).
High Dividend: ABT's dividend (1.75%) is low compared to the top 25% of dividend payers in the US market (4.51%).
Earnings Payout to Shareholders
Earnings Coverage: With its reasonably low payout ratio (29.2%), ABT's dividend payments are well covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: With its reasonable cash payout ratio (63.1%), ABT's dividend payments are covered by cash flows.
Discover strong dividend paying companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/02/22 03:50 |
| End of Day Share Price | 2025/02/21 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Abbott Laboratories is covered by 59 analysts. 26 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| David Toung | Argus Research Company |
| Stephan Gasteyger | Atlantic Equities LLP |
| Ishan Majumdar | Baptista Research |